A180400 Stock Overview
Engages in the development and sale of bio-health care products and provides molecular genetic testing services primarily in South Korea. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 2/6 |
| Dividends | 0/6 |
Dx & Vx Co., Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₩1,780.00 |
| 52 Week High | ₩7,280.00 |
| 52 Week Low | ₩1,639.00 |
| Beta | -0.056 |
| 11 Month Change | -25.68% |
| 3 Month Change | -55.83% |
| 1 Year Change | -68.94% |
| 33 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -63.22% |
Recent News & Updates
Recent updates
Positive Sentiment Still Eludes Dx & Vx Co., Ltd. (KOSDAQ:180400) Following 27% Share Price Slump
Oct 21
Market Cool On Dx & Vx Co., Ltd.'s (KOSDAQ:180400) Revenues Pushing Shares 39% Lower
Jul 15Dx & Vx Co., Ltd. (KOSDAQ:180400) Might Not Be As Mispriced As It Looks After Plunging 37%
May 31Investors Give Dx & Vx Co., Ltd. (KOSDAQ:180400) Shares A 25% Hiding
Mar 18Dx & Vx (KOSDAQ:180400) Is Carrying A Fair Bit Of Debt
Mar 08Shareholder Returns
| A180400 | KR Biotechs | KR Market | |
|---|---|---|---|
| 7D | -10.6% | -8.1% | 2.9% |
| 1Y | -68.9% | 18.1% | -2.8% |
Return vs Industry: A180400 underperformed the KR Biotechs industry which returned 21.1% over the past year.
Return vs Market: A180400 underperformed the KR Market which returned -4% over the past year.
Price Volatility
| A180400 volatility | |
|---|---|
| A180400 Average Weekly Movement | 15.1% |
| Biotechs Industry Average Movement | 8.0% |
| Market Average Movement | 5.6% |
| 10% most volatile stocks in KR Market | 11.5% |
| 10% least volatile stocks in KR Market | 2.7% |
Stable Share Price: A180400's share price has been volatile over the past 3 months compared to the KR market.
Volatility Over Time: A180400's weekly volatility (15%) has been stable over the past year, but is still higher than 75% of KR stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2001 | 114 | Yong Gu Lee | www.dxvx.com |
Dx & Vx Co., Ltd. engages in the development and sale of bio-health care products and provides molecular genetic testing services primarily in South Korea. The company offers healthcare products, including Ofmom Carefree, oat fermented food, and biocleaners; diagnostic products, comprising CLIDEX, precision diagnostics, and in vitro diagnostic kit; health check services; CDx development services; medical data; and funeral home operation services. It provides bacterial vaccine for respiratory disease; macular degeneration drug; atopy dermatitis drugs; xeropthalmia drugs; anticancer vaccine; and new antibody drugs.
Dx & Vx Co., Ltd. Fundamentals Summary
| A180400 fundamental statistics | |
|---|---|
| Market cap | ₩87.61b |
| Earnings (TTM) | -₩27.69b |
| Revenue (TTM) | ₩45.34b |
1.9x
P/S Ratio-3.2x
P/E RatioIs A180400 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| A180400 income statement (TTM) | |
|---|---|
| Revenue | ₩45.34b |
| Cost of Revenue | ₩34.87b |
| Gross Profit | ₩10.46b |
| Other Expenses | ₩38.15b |
| Earnings | -₩27.69b |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -562.57 |
| Gross Margin | 23.08% |
| Net Profit Margin | -61.07% |
| Debt/Equity Ratio | 338.7% |
How did A180400 perform over the long term?
See historical performance and comparison